Verona Pharma PLC
NASDAQ:VRNA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.48
39.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
VRNA Price Targets Summary
Verona Pharma PLC
According to Wall Street analysts, the average 1-year price target for VRNA is 46.73 USD with a low forecast of 36.36 USD and a high forecast of 67.2 USD.
VRNA Last Price Targets
Verona Pharma PLC
The latest public price target was made on Nov 5, 2024 by Raghuram Selvaraju from H.C. Wainwright , who expects VRNA stock to rise by 8% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.
Analyst | Price Target | Date | Article |
---|---|---|---|
Raghuram Selvaraju
H.C. Wainwright
|
42
USD
Upside 8% |
2 weeks ago
Nov 5, 2024
|
Verona Pharma (VRNA) PT Raised to $42 at H.C. Wainwright
StreetInsider
|
Edward Nash
Canaccord Genuity
|
37
USD
Downside 5% |
4 months ago
Jul 22, 2024
|
Verona Pharma (VRNA) PT Raised to $37 at Canaccord Genuity
StreetInsider
|
Raghuram Selvaraju
H.C. Wainwright
|
36
USD
Downside 7% |
4 months ago
Jun 27, 2024
|
Verona Pharma price target raised to $36 from $32 at H.C. Wainwright
TheFly
|
Andrew Tsai
Jefferies
|
38
USD
Downside 2% |
5 months ago
May 28, 2024
|
Expert likely to prescribe more ensifentrine than dupixent, says Jefferies
TheFly
|
Yasmeen Rahimi
Piper Sandler
|
36
USD
Downside 7% |
7 months ago
Apr 16, 2024
|
Verona Pharma (VRNA) PT Raised to $36 at Piper Sandler
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VRNA's stock price target?
Price Target
46.73
USD
According to Wall Street analysts, the average 1-year price target for VRNA is 46.73 USD with a low forecast of 36.36 USD and a high forecast of 67.2 USD.